Citadel Advisors
HSTO

Citadel Advisors’s Histogen Inc. Common Stock HSTO Stock Holding History

Citadel Advisors’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$5K – 9986
2019
Q2 		$5K Sell
100
-270
-73% -$46.9K ﹤0.01% 9073
2019
Q1 		$80K Sell
370
-195
-35% -$78.6K ﹤0.01% 8641
2018
Q4 		$195K Buy
565
+303
+116% +$235K ﹤0.01% 7886
2018
Q3 		$304K Buy
262
+92
+54% +$84.8K ﹤0.01% 7537
2018
Q2 		$146K Buy
170
+83
+95% +$68.9K ﹤0.01% 8083
2018
Q1 		$102K Buy
87
+37
+74% +$40.9K ﹤0.01% 7704
2017
Q4 		$46K Buy
+50
New +$46.2K ﹤0.01% 7655
2017
Q3 		– Sell
-104
Closed -$120K – 8244
2017
Q2 		$120K Hold
104
– – ﹤0.01% 6841
2017
Q1 		$120K Sell
104
-14
-12% -$13.5K ﹤0.01% 6789
2016
Q4 		$124K Buy
+118
New +$53.6K ﹤0.01% 6590

Other funds holding HSTO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's HSTO Position: Q3 2022 in Review

Citadel Advisors sold out of Histogen Inc. Common Stock (HSTO) in Q3 2022, closing a stake of 10,551 shares — an estimated $24K sold.

Citadel Advisors first reported a position in HSTO in Q2 2015 and held it in 23 quarters. The position peaked at $1.69M in Q3 2015. 13 funds tracked by Wall St. Rank hold HSTO as of Q3 2022.

  • Citadel Advisors reported no remaining Histogen Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 10,551 Histogen Inc. Common Stock shares in Q3 2022, an estimated $24K.
  • Citadel Advisors first reported a position in Histogen Inc. Common Stock in Q2 2015 and held it in 23 quarters.
  • Citadel Advisors's Histogen Inc. Common Stock position peaked at $1.69M in Q3 2015.
  • 13 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.